Dividend Stock Portfolio for Retirement: Pfizer's (PFE) Reliable Payouts

Pfizer Inc. (NYSE:PFE)  is included among the Best Retirement Stocks for a Dividend Stock Portfolio.

Pfizer Inc. (NYSE:PFE) is an American multinational pharmaceutical and biotech company. The last three years have been challenging for its investors. The company’s COVID-19 vaccine and treatment initially sent the stock soaring during the pandemic, but once demand peaked, the share price followed suit. The stock has declined by nearly 50% over the past three years.

Looking ahead, Pfizer Inc. (NYSE:PFE)’s pipeline offers potential for future growth even though it has not yet translated into new revenue. Among its most notable candidates are Elrexfio (elranatamab-bcmm) and Sigvotatug vedotin. Elrexfio is already approved for certain multiple myeloma patients, and ongoing phase 3 trials could significantly expand its use. Sigvotatug vedotin, an antibody-drug conjugate acquired through Pfizer’s 2023 purchase of Seagen, has shown strong results in phase 3 trials as a treatment for advanced lung cancer.

In total, Pfizer Inc. (NYSE:PFE)currently has 18 oncology drugs in phase 3 development, with eight of them projected to potentially generate over $1 billion in annual sales each by 2030. Moreover, the company’s dividend is keeping it afloat in times like these. It has been growing its dividends for 15 consecutive years and currently pays a quarterly dividend of $0.43 per share. As of September 21, the stock has a dividend yield of 7.16%.

While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best S&P 500 Dividend Stocks to Invest in and 10 Safest High Dividend Stocks to Buy Now

Disclosure: None.